Isomorphic Labs
PulseAugur coverage of Isomorphic Labs — every cluster mentioning Isomorphic Labs across labs, papers, and developer communities, ranked by signal.
- spun off from John Michael Jumper 90%
- spun off from Novartis 90%
- founded Novartis 90%
- invested by Thrive Capital 90%
- spun off from Eli Lilly and Company 90%
- affiliated with Alphabet Inc. 70%
- parent of Alphabet Inc. 70%
- competes with Alphabet Inc. 70%
- employed by John Michael Jumper 70%
- founded Jeff Dean 70%
- founded by Jeff Dean 70%
- invested by Jeff Dean 70%
- 2026-07-17 product_launch Isomorphic Labs launched its Drug Design Engine, a new platform for drug discovery. source
- 2026-06-11 product_launch Isomorphic Labs is developing advanced protein modeling tools to accelerate AI-driven drug discovery. source
- 2026-05-27 funding Isomorphic Labs secured $2.1 billion in Series B funding led by Thrive Capital to accelerate its AI drug discovery efforts. source
- 2026-05-13 funding Isomorphic Labs secured $2.1 billion in Series B funding. source
- 2026-05-12 funding Isomorphic Labs secured $2.1 billion in Series B funding.
- 2026-05-12 funding Isomorphic Labs raised $2.1 billion in a Series B funding round.
- 2026-04-24 funding Isomorphic Labs closed a $2.1 billion Series B funding round led by Thrive Capital. source
4 day(s) with sentiment data
-
ByteDance spin-off Anew Labs raises $290M for AI drug discovery
Anew Labs, a former unit of ByteDance, has secured US$290 million in funding at a US$1.5 billion valuation. The Shanghai-based AI drug discovery firm's funding round was backed by prominent venture capital firms includi…
-
Google DeepMind releases AI-powered AlphaGenome Atlas for 9 billion DNA variants · 9 sources tracked
Google DeepMind has launched the AlphaGenome Atlas, a comprehensive database that uses AI to predict the molecular effects of approximately 9 billion possible single-nucleotide variants in the human genome. This resourc…
-
AI giants pivot to health care to boost image and investor confidence · 1 source tracked
Major AI companies are increasingly focusing on health care applications to improve their public image and secure investor confidence. This strategic shift aims to counter negative perceptions surrounding AI's environme…
-
AI in Drug Discovery: Algorithms vs. Full Pipeline Value
Two recent AI-driven pharmaceutical developments, one from Anthropic and another from Moderna, have generated significant public interest. Anthropic utilized its Claude model to autonomously design protein binders for 1…
-
US patent law struggles to credit AI inventors in drug discovery
Intellectual property law currently faces a significant challenge as artificial intelligence systems are increasingly capable of generating novel drug designs. Despite AI's role in these discoveries, current patent laws…
-
Startup Vivodyne claims AI drug discovery needs better human data
A biotech startup named Vivodyne claims that the current AI drug-discovery field is hampered by a lack of high-quality, human-centric data. Vivodyne has developed modular robotic labs, called HIVE, capable of generating…
-
AI in Drug Discovery: Progress, Challenges, and Future Outlook · 4 sources tracked
Multiple sources discuss the current state and future trajectory of artificial intelligence in drug discovery. While AI has shown promise in accelerating the identification and development of new medicines, its real-wor…
-
Demis Hassabis reportedly considering reduced role at Google to focus on Isomorphic Labs
Demis Hassabis, Google's Chief Scientist, is reportedly considering a reduced role or departure from the company. Speculation suggests he wishes to focus more on Isomorphic Labs, a company he chairs. There is also conje…
-
Demis Hassabis's Google DeepMind Role Shift Sparks Promotion vs. Demotion Debate
Demis Hassabis has transitioned from CEO of Google DeepMind to Chief Scientist, sparking debate about whether this move was a promotion or a demotion. Supporters suggest it allows him to focus more on research and Isomo…
-
Google reshuffles AI leadership: Hassabis to Alphabet chair, Dean departs
Google has undergone a significant restructuring of its AI leadership. Demis Hassabis is transitioning to the role of Alphabet chair and chief scientist, while still overseeing Isomorphic Labs. Concurrently, Jeff Dean, …
-
Google reshapes AI leadership: Hassabis moves up, Dean departs for startup
Google has undergone a significant AI leadership shake-up, with Demis Hassabis stepping down from his daily operational role at Google DeepMind to become Alphabet's chief scientist and chair of Google DeepMind. Jeff Dea…
-
Google DeepMind CEO Demis Hassabis steps down; Jeff Dean departs for AI startup
Google DeepMind CEO Demis Hassabis is stepping down from his day-to-day management role to become the chairman of Google DeepMind and chief scientist for Alphabet. Koray Kavukcuoglu, the current CTO, will take over dail…
-
OpenAI slashes GPT-5.6 prices; AI lab staff call for development slowdown · 2 sources tracked
OpenAI has significantly reduced prices for its GPT-5.6 Luna model, cutting costs by 80% just weeks after its launch, attributing the decrease to internal efficiency gains. Meanwhile, a group of employees from major AI …
-
Google DeepMind disbands AlphaFold team; Nobel laureates join Anthropic
Google DeepMind has disbanded its renowned AlphaFold team, which was instrumental in solving protein structure prediction and included Nobel laureates. While Google states the team's expertise is being redirected to bro…
-
Google shutters Nobel-winning AlphaFold AI project to focus on Gemini
Google has reportedly shut down its Nobel Prize-winning AlphaFold project, reassigning its team members to focus on Gemini-related initiatives. AlphaFold, an AI program developed by Google DeepMind, revolutionized prote…
-
Isomorphic Labs unveils new engine surpassing AlphaFold for drug design
Isomorphic Labs has unveiled its Drug Design Engine (IsoDDE), a computational platform designed to advance drug discovery beyond the capabilities of AlphaFold. This new engine demonstrates superior accuracy in predictin…
-
Ex-OpenAI Researcher's AI Drug Startup Nears $2B Valuation
A former OpenAI researcher, Miles Wang, has left the company to co-found an AI drug discovery startup, which is reportedly in talks for a $200 million funding round at a $2 billion valuation. This move highlights a grow…
-
Google DeepMind and Isomorphic Labs launch bioresilience initiative
Google DeepMind and Isomorphic Labs have launched a bioresilience initiative aimed at mitigating the misuse of advanced AI in biological contexts while simultaneously enhancing capabilities for outbreak detection and re…
-
Google DeepMind partners with Isomorphic Labs on AI for biosecurity
Google DeepMind is collaborating with Isomorphic Labs to address the evolving biosecurity landscape. The partnership aims to develop proactive defenses for global health by leveraging advanced AI technologies. This init…
-
Google DeepMind and Isomorphic Labs partner on AI for bioresilience
Google DeepMind and Isomorphic Labs are collaborating on a bioresilience program to leverage AI for preventing, detecting, and responding to biological threats. Their approach involves ensuring AI models are not misused…